AU2001247737A1 - Methods of therapy for non-hodgkin's lymphoma using a combination of an antibodyto cd20 and interleuking-2 - Google Patents

Methods of therapy for non-hodgkin's lymphoma using a combination of an antibodyto cd20 and interleuking-2

Info

Publication number
AU2001247737A1
AU2001247737A1 AU2001247737A AU4773701A AU2001247737A1 AU 2001247737 A1 AU2001247737 A1 AU 2001247737A1 AU 2001247737 A AU2001247737 A AU 2001247737A AU 4773701 A AU4773701 A AU 4773701A AU 2001247737 A1 AU2001247737 A1 AU 2001247737A1
Authority
AU
Australia
Prior art keywords
antibodyto
interleuking
hodgkin
lymphoma
therapy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001247737A
Other languages
English (en)
Inventor
Joseph D Rosenblatt
Maurice J. Wolin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis Vaccines and Diagnostics Inc
University of Rochester
Original Assignee
University of Rochester
Chiron Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Rochester, Chiron Corp filed Critical University of Rochester
Publication of AU2001247737A1 publication Critical patent/AU2001247737A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU2001247737A 2000-03-24 2001-03-23 Methods of therapy for non-hodgkin's lymphoma using a combination of an antibodyto cd20 and interleuking-2 Abandoned AU2001247737A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US19204700P 2000-03-24 2000-03-24
US60192047 2000-03-24
PCT/US2001/009413 WO2001072333A1 (en) 2000-03-24 2001-03-23 Methods of therapy for non-hodgkin's lymphoma using a combination_of an antibody to cd20 and interleuking-2

Publications (1)

Publication Number Publication Date
AU2001247737A1 true AU2001247737A1 (en) 2001-10-08

Family

ID=22708018

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001247737A Abandoned AU2001247737A1 (en) 2000-03-24 2001-03-23 Methods of therapy for non-hodgkin's lymphoma using a combination of an antibodyto cd20 and interleuking-2

Country Status (7)

Country Link
US (1) US20020009427A1 (https=)
EP (1) EP1267927A1 (https=)
JP (1) JP2003528155A (https=)
AU (1) AU2001247737A1 (https=)
CA (1) CA2404390A1 (https=)
IL (1) IL151906A0 (https=)
WO (1) WO2001072333A1 (https=)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001060397A1 (en) * 2000-02-16 2001-08-23 Genentech, Inc. Uses of agonists and antagonists to modulate activity of tnf-related molecules
WO2000067796A1 (en) 1999-05-07 2000-11-16 Genentech, Inc. Treatment of autoimmune diseases with antagonists which bind to b cell surface markers
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
BR0211614A (pt) * 2001-08-03 2006-10-31 Genentech Inc polipeptìdeo tacis e br3 e empregos dos mesmos
CA2469045A1 (en) * 2001-12-07 2003-06-19 Chiron Corporation Methods of therapy for non-hodgkin's lymphoma
WO2003068821A2 (en) * 2002-02-14 2003-08-21 Immunomedics, Inc. Anti-cd20 antibodies and fusion proteins thereof and methods of use
US8287864B2 (en) * 2002-02-14 2012-10-16 Immunomedics, Inc. Structural variants of antibodies for improved therapeutic characteristics
WO2004011611A2 (en) * 2002-07-25 2004-02-05 Genentech, Inc. Taci antibodies and uses thereof
AU2015205832A1 (en) * 2002-10-17 2015-08-13 Genmab A/S Human Monoclonal Antibodies Against CD20
AU2011202520C1 (en) * 2002-10-17 2016-02-18 Genmab A/S Human monoclonal antibodies against CD20
BRPI0315295C1 (pt) * 2002-10-17 2021-05-25 Genmab As anticorpo monoclonal humano isolado, célula hospedeira procariótica, composição farmacêutica, molécula biespecífica, usos de um anticorpo, métodos in vitro de detectar a presença de antígeno de cd20 ou uma célula que expressa cd20 em uma amostra, kit, e, vetor de expressão
TWI335821B (en) 2002-12-16 2011-01-11 Genentech Inc Immunoglobulin variants and uses thereof
EP1613350B1 (en) 2003-04-09 2009-03-18 Genentech, Inc. Therapy of autoimmune disease in a patient with an inadequate response to a tnf-alpha inhibitor
US20050163775A1 (en) * 2003-06-05 2005-07-28 Genentech, Inc. Combination therapy for B cell disorders
JP2007526220A (ja) 2003-06-05 2007-09-13 ジェネンテック・インコーポレーテッド Ｂ細胞疾患の併用療法
US7850962B2 (en) * 2004-04-20 2010-12-14 Genmab A/S Human monoclonal antibodies against CD20
ZA200608982B (en) * 2004-05-05 2008-06-25 Genentech Inc Preventing autoimmune disease by using an anti-CD20 antibody
MXPA06014067A (es) * 2004-06-04 2007-02-15 Genentech Inc Metodo para tratar lupus.
AU2005249566B2 (en) * 2004-06-04 2010-11-11 Genentech, Inc. Method for treating multiple sclerosis
BRPI0513100A (pt) * 2004-07-22 2007-10-23 Genentech Inc métodos de tratamento da sìndrome de sjÍgren e artigos manufaturados
BRPI0516297A (pt) * 2004-10-05 2008-09-02 Genentech Inc métodos de tratamento de vasculite e artigos de fabricação
TW200637574A (en) * 2005-01-13 2006-11-01 Genentech Inc Treatment method
DOP2006000029A (es) * 2005-02-07 2006-08-15 Genentech Inc Antibody variants and uses thereof. (variantes de un anticuerpo y usos de las mismas)
TW200714289A (en) * 2005-02-28 2007-04-16 Genentech Inc Treatment of bone disorders
US8349332B2 (en) 2005-04-06 2013-01-08 Ibc Pharmaceuticals, Inc. Multiple signaling pathways induced by hexavalent, monospecific and bispecific antibodies for enhanced toxicity to B-cell lymphomas and other diseases
US8475794B2 (en) 2005-04-06 2013-07-02 Ibc Pharmaceuticals, Inc. Combination therapy with anti-CD74 antibodies provides enhanced toxicity to malignancies, Autoimmune disease and other diseases
AR053579A1 (es) * 2005-04-15 2007-05-09 Genentech Inc Tratamiento de la enfermedad inflamatoria intestinal (eii)
ZA200709956B (en) 2005-05-20 2009-02-25 Genentech Inc Pretreatment of a biological sample from an autoimmune disease subject
RU2421242C2 (ru) 2005-07-25 2011-06-20 Трабьон Фармасьютикалз, Инк. Применение однократной дозы cd20-специфических связывающих молекул
RU2423381C2 (ru) 2005-07-25 2011-07-10 Трабьон Фармасьютикалз, Инк. Снижение количества в-клеток с использованием cd37-специфических и cd20-специфических связывающих молекул
MY149159A (en) 2005-11-15 2013-07-31 Hoffmann La Roche Method for treating joint damage
ES2618543T3 (es) * 2005-11-23 2017-06-21 Genentech, Inc. Métodos y composiciones relacionados con ensayos de linfocitos B
NZ573646A (en) 2006-06-12 2012-04-27 Wyeth Llc Single-chain multivalent binding proteins with effector function
KR102055873B1 (ko) 2007-07-09 2019-12-13 제넨테크, 인크. 폴리펩티드의 재조합 생산 동안의 디술피드 결합 환원의 방지
HUE030134T2 (en) 2007-10-16 2017-04-28 Zymogenetics Inc Combination of transmembrane activator and calcium modulator and cyclophilin ligand interactor (TACI) and anti-CD20 agents for the treatment of autoimmune diseases
EP2077281A1 (en) 2008-01-02 2009-07-08 Bergen Teknologioverforing AS Anti-CD20 antibodies or fragments thereof for the treatment of chronic fatigue syndrome
US7914785B2 (en) * 2008-01-02 2011-03-29 Bergen Teknologieverforing As B-cell depleting agents, like anti-CD20 antibodies or fragments thereof for the treatment of chronic fatigue syndrome
RU2531754C2 (ru) 2008-04-11 2014-10-27 ЭМЕРДЖЕНТ ПРОДАКТ ДИВЕЛОПМЕНТ СИЭТЛ,ЭлЭлСи,US Связывающееся с cd37 иммунотерапевтическое средство и его комбинация с бифункциональным химиотерапевтическим средством
CN102159243B (zh) * 2008-07-21 2015-08-19 免疫医疗公司 用于改良的治疗特征的抗体的结构变体
AR073295A1 (es) 2008-09-16 2010-10-28 Genentech Inc Metodos para tratar la esclerosis multiple progresiva. articulo de fabricacion.
WO2010075249A2 (en) 2008-12-22 2010-07-01 Genentech, Inc. A method for treating rheumatoid arthritis with b-cell antagonists
US20110142836A1 (en) * 2009-01-02 2011-06-16 Olav Mella B-cell depleting agents for the treatment of chronic fatigue syndrome
HRP20200768T4 (hr) 2009-08-11 2025-03-28 F. Hoffmann - La Roche Ag Proizvodnja proteina u mediju za uzgoj stanica bez glutamina
CN102050879B (zh) * 2009-10-30 2014-02-19 上海抗体药物国家工程研究中心有限公司 抗人cd20人源化抗体、其制备方法及用途
AU2010257199A1 (en) * 2009-12-15 2011-06-30 Guvera Ip Pty Ltd A System and Method For Producing And Displaying Content Representing A Brand Persona
KR20130009760A (ko) 2010-02-10 2013-01-23 이뮤노젠 아이엔씨 Ｃｄ２０ 항체 및 이의 용도
US9844582B2 (en) * 2012-05-22 2017-12-19 Massachusetts Institute Of Technology Synergistic tumor treatment with extended-PK IL-2 and therapeutic agents
EP3303373B1 (en) 2015-05-30 2020-04-08 Molecular Templates, Inc. De-immunized, shiga toxin a subunit scaffolds and cell-targeting molecules comprising the same
HUE057952T2 (hu) 2015-06-24 2022-06-28 Hoffmann La Roche Anti-transzferrin receptor antitestek testreszabott affinitással
WO2017053469A2 (en) 2015-09-21 2017-03-30 Aptevo Research And Development Llc Cd3 binding polypeptides
TWI873952B (zh) 2015-10-02 2025-02-21 瑞士商赫孚孟拉羅股份公司 雙特異性抗‐人類cd20/人類轉鐵蛋白受體抗體及使用方法
AR106189A1 (es) 2015-10-02 2017-12-20 Hoffmann La Roche ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4931543A (en) * 1987-05-11 1990-06-05 Cetus Corporation Process for recovering microbially produced interleukin-2
PT1974747E (pt) * 1998-08-11 2012-09-05 Biogen Idec Inc Terapias de combinação para linfomas de células b compreendendo a administração de anticorpo anti-cd20

Also Published As

Publication number Publication date
CA2404390A1 (en) 2001-10-04
IL151906A0 (en) 2003-04-10
US20020009427A1 (en) 2002-01-24
JP2003528155A (ja) 2003-09-24
WO2001072333A1 (en) 2001-10-04
EP1267927A1 (en) 2003-01-02

Similar Documents

Publication Publication Date Title
AU2001247737A1 (en) Methods of therapy for non-hodgkin's lymphoma using a combination of an antibodyto cd20 and interleuking-2
AU6045298A (en) Method and device for soft tissue modification
AU2577299A (en) Implantable therapeutic device and method
AU4962596A (en) Device and methods for plasma sterilization
AU703128B2 (en) Device in inhalers
AU1603495A (en) Instrument and method for incising into body
AU2024500A (en) Intraoral electromuscular stimulation device and method
AU4690699A (en) Apparatus and methods for entering cavities of the body
AU2001283546A1 (en) Inhalation device and method
AU2797499A (en) Tissue penetrating device and methods for using same
AU4968796A (en) Soft tissue containing glycerin and quaternary ammonium compounds
AU3905099A (en) Medical instrument and method for eye capsulotomy
AU2002212017A1 (en) Technique and apparatus for ultrasound therapy
AU5036198A (en) Methods and devices for collection of soft tissue
AU2001292297A1 (en) Mouthpiece for orthodontic treatment and device for orthodontic treatment using the mouthpiece
AU2002309523A1 (en) A brachytherapy device and method of use
AU2002362098A1 (en) Methods of therapy for non-hodgkin's lymphoma
AU8967998A (en) Antibiotic-ligand conjugates and methods of use thereof
AU2320299A (en) Device and method for radiation therapy
AU7275000A (en) Absorbent body for an absorbent product and methods for producing an absorbent body
AU2077999A (en) Device and method for cultivating shellfish
AU2001287890A1 (en) Radiotherapy apparatus and collimator set therefor
AU2001282240A1 (en) Method for generating nanostructures and device generating nanostructures
AU6198299A (en) Device and method for sterilising screwcaps
AU3468499A (en) Data-imprinted dental radiograph device and process